keyword
https://read.qxmd.com/read/38222185/implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice
#41
JOURNAL ARTICLE
Shamas U Din, Muhammad Ahmed Saeed, Muhammad R Hameed, Maryam Aamer, Umbreen Arshad, Hafiz Yasir Qamar
Background Measuring disease activity in psoriatic arthritis using validated tools and treating to a target (T2T) is advocated. It improves quality of life and delays radiographic progression. In clinical practice, it guides therapy escalation to achieve better disease control. This study aimed to assess the real-life implementation of the T2T concept in daily clinical practice and the proportion of patients achieving the target of low disease activity or remission. Methodology In this study, a retrospective review of patients diagnosed with psoriatic arthritis having clinical visits from January 2020 to February 2023 was done...
December 2023: Curēus
https://read.qxmd.com/read/38222129/review-of-teratogenic-effects-of-leflunomide-accutane-thalidomide-warfarin-tetracycline-and-angiotensin-converting-enzyme-inhibitors
#42
REVIEW
Raegan B Abadie, Camryn L Keller, Nicholas T Jones, Erin L Mayeux, Rachel J Klapper, Lillian Anderson, Adam M Kaye, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye
Teratogenic agents have been shown to have drastic and detrimental effects on fetuses if exposed to the agent during uterine life. The most sensitive time for a developing fetus is during the first trimester, and teratogenic exposure during this time can lead to severe deformities in the fetus. The Food and Drug Administration has categorized teratogenic agents based on the severity of their effect on the fetus; these categories include A, B, C, D, and X. Category A is the safest, with the most dangerous, and highly contraindicated in pregnant patients being Category X...
December 2023: Curēus
https://read.qxmd.com/read/38192103/novel-management-of-masticatory-myositis-in-three-dogs-with-a-selective-janus-kinase-jak-1-inhibitor
#43
JOURNAL ARTICLE
Michael C Congiusta, Christopher Snyder, Jason W Soukup, Neoklis Apostolopoulos
Masticatory myositis (MM) is an inflammatory myopathy reported in dogs and is characterized by inflammation of the masticatory muscles (temporalis, masseter, and pterygoid muscles). Immunosuppressive therapy is the current recommended treatment for MM and may involve glucocorticoids, cyclosporine, azathioprine, mycophenolate mofetil, leflunomide, or a combination of these treatments that are slowly tapered to the lowest effective dose. However, side effects from multimodal medical therapy and complications associated with MM relapses have been reported...
January 8, 2024: Journal of Veterinary Dentistry
https://read.qxmd.com/read/38175978/leflunomide-for-the-treatment-of-immune-mediated-uveitis-in-a-dog
#44
JOURNAL ARTICLE
Se Eun Kim
A 5 yr old castrated male bichon frise presented with chronic bilateral uveitis that had previously been controlled with systemic steroid administration for 6 mo, resulting in weight gain, polyuria, and polydipsia. To control the uveitis without systemic side effects, oral cyclosporine was started after discontinuing oral steroid, but discontinued one month later because of severe vomiting. Leflunomide (2 mg/kg q 12 hr) was initiated, and the uveitis symptoms resolved after 2 mo. The dose was tapered according to the remission of clinical signs, with no relapse during the following 13 mo...
January 1, 2024: Journal of the American Animal Hospital Association
https://read.qxmd.com/read/38174776/immunomodulators-and-immunosuppressants-for-relapsing-remitting-multiple-sclerosis-a-network-meta-analysis
#45
REVIEW
Marien Gonzalez-Lorenzo, Ben Ridley, Silvia Minozzi, Cinzia Del Giovane, Guy Peryer, Thomas Piggott, Matteo Foschi, Graziella Filippini, Irene Tramacere, Elisa Baldin, Francesco Nonino
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse frequency and slows disability accumulation compared to no treatment, their relative benefit remains unclear. This is an update of a Cochrane review published in 2015. OBJECTIVES: To compare the efficacy and safety, through network meta-analysis, of interferon beta-1b, interferon beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1-a and beta 1-b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS...
January 4, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38174153/bk-viral-infection-a-review-of-management-and-treatment
#46
REVIEW
June Hayrelle Gorriceta, Amy Lopez Otbo, Genta Uehara, Maria Aurora Posadas Salas
BK viral infection remains to be a challenging post-transplant infection, which can result in kidney dysfunction. The mainstay approach to BK infection is reduction of immunosuppression. Alterations in immunosuppressive regimen with minimization of calcineurin inhibitors, use of mechanistic target of rapamycin inhibitors, and leflunomide have been attempted with variable outcomes. Over the past few years, investigators have explored potential therapeutic options for BK infection. Fluoroquinolone prophylaxis and treatment was found to have no benefit in kidney transplant recipients...
December 18, 2023: World Journal of Transplantation
https://read.qxmd.com/read/38171692/folate-decorated-chitosan-chondroitin-sulfate-nanoparticles-loaded-hydrogel-for-targeting-macrophages-against-rheumatoid-arthritis
#47
JOURNAL ARTICLE
Bazla Siddiqui, Asim Ur Rehman, Rabia Gul, Iqra Chaudhery, Kifayat Ullah Shah, Naveed Ahmed
Inflammatory cell infiltration, particularly macrophages, plays a major contribution to the pathogenesis of Rheumatoid Arthritis (RA). Exploiting the overexpression of folate receptors (FR-β) on these recruited macrophages has gained significant attraction for ligand-targeted delivery. Leflunomide (LEF), being an immunomodulatory agent is considered the cornerstone of the therapy, however, its oral efficacy is impeded by low solubility and escalating adverse effects profile. Therefore, in the present work, we developed Folate-conjugated chitosan-chondroitin sulfate nanoparticles encapsulating LEF for selective targeting at inflammatory sites in RA...
March 1, 2024: Carbohydrate Polymers
https://read.qxmd.com/read/38149668/treatment-of-bk-polyomavirus-associated-nephropathy-in-paediatric-kidney-transplant-recipients-leflunomide-versus-cidofovir
#48
JOURNAL ARTICLE
Gülşah Kaya Aksoy, Mine Erkan, Mustafa Koyun, Elif Çomak, Havva Serap Toru, Derya Mutlu, Bahar Akkaya, Sema Akman
OBJECTIVES: BK polyomavirus-associated nephropathy is a clinicopathological entity that negatively affects graft function in kidney transplant recipients. We compared the efficacy of leflunomide and cidofovir to treat BK polyomavirus-associated nephropathy in pediatric kidney transplant recipients. MATERIALS AND METHODS: Medical records of pediatric recipients with BK viremia for the period 2004 through 2019 were reviewed retrospectively, and patients diagnosed with BK polyomavirusassociated nephro-pathy were included in the study...
December 26, 2023: Experimental and Clinical Transplantation
https://read.qxmd.com/read/38126739/advances-in-non-biological-drugs-for-the-treatment-of-rheumatoid-arthritis
#49
REVIEW
Aliki I Venetsanopoulou, Paraskevi V Voulgari, Alexandros A Drosos
INTRODUCTION: Rheumatoid arthritis (RA) is a complex autoimmune disease that affects millions of people worldwide, with a systemic impact. This review explores the role of non-biological conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in its management. AREAS COVERED: We discuss the effectiveness and safety of key csDMARDs such as Nonsteroidal anti-inflammatory drugs, corticosteroids, Hydroxychloroquine, Sulfasalazine, Methotrexate, and Leflunomide in relieving symptoms and slowing the progression of the disease...
2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38110986/role-of-mitochondrial-fusion-proteins-mfn2-and-opa1-on-lung-cellular-senescence-in-chronic-obstructive-pulmonary-disease
#50
JOURNAL ARTICLE
Chenfei Li, Qi Liu, Qing Chang, Meiqin Xie, Jiali Weng, Xiaohui Wang, Mengnan Li, Jiani Chen, Yan Huang, Xiaohua Yang, Kai Wang, Na Zhang, Kian Fan Chung, Ian M Adcock, Hai Zhang, Feng Li
BACKGROUND: Mitochondrial dysfunction and lung cellular senescence are significant features involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Cigarette smoke (CS) stands as the primary contributing factor to COPD. This study examined mitochondrial dynamics, mitophagy and lung cellular senescence in COPD patients and investigated the effects of modulation of mitochondrial fusion [mitofusin2 (MFN2) and Optic atrophy 1 (OPA1)] on CS extract (CSE)-induced lung cellular senescence...
December 18, 2023: Respiratory Research
https://read.qxmd.com/read/38101913/aneurysmal-disease-in-patients-with-takayasu-arteritis
#51
JOURNAL ARTICLE
Frédéric Lefebvre, Carolyn Ross, Medha Soowamber, Christian Pagnoux
OBJECTIVE: Takayasu Arteritis (TAK) leads to stenotic disease. Aneurysmal lesions are rarer. This study assessed the main characteristics of aneurysmal disease in a Canadian cohort of TAK patients. METHODS: This monocentric retrospective study included TAK patients, followed at Mount Sinai Vasculitis Clinic (Toronto). Diagnosis of TAK was based on clinical findings and/or satisfied the 1990 ACR classification criteria. RESULTS: 74 patients were included...
December 15, 2023: Journal of Rheumatology
https://read.qxmd.com/read/38101782/-effectiveness-of-tofacitinib-combined-with-iguratimod-in-the-treatment-of-difficult-to-treat-moderate-to-severe-rheumatoid-arthritis
#52
JOURNAL ARTICLE
Xue Zou, Xiao Juan Bai, Li Qing Zhang
OBJECTIVE: To investigate the efficacy and safety of iguratimod combined with tofacitinib in patients with difficult-to-treat moderate-to-severe rheumatoid arthritis (RA). METHODS: In this prospective clinical study, 30 patients with difficult-to-treat moderate-to-severe RA who attended the Department of Rheumatology and Immunology of Shanxi Province Fenyang Hospital from September 2021 to June 2022 were selected. Twenty-three patients enrollment had been treated with 2 or more conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) for more than 6 months...
December 18, 2023: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://read.qxmd.com/read/38087473/the-efficacy-of-immunosuppressive-drugs-induction-therapy-for-lupus-nephritis-a-systematic-review-and-network-meta-analysis
#53
REVIEW
Yongqiang Dong, Jinmin Shi, Shanshan Wang, Yanhong Liu, Shirong Yu, Lijun Zhao
OBJECTIVE: This study was to assess the safety and effectiveness of immunosuppressive agents, specifically Voclosporin, when used in conjunction with mycophenolate mofetil (MMF) induction therapy for the management of lupus nephritis (LN). METHODS: A systematic review and network meta-analysis (NMA) was conducted on randomized controlled trials investigating the efficacy of immunosuppressant-induced therapy for LN. The random effects model was used in the analysis...
2023: Renal Failure
https://read.qxmd.com/read/38087262/retrospective-evaluation-of-prognosis-and-survival-with-various-immunosuppressants-in-82-dogs-diagnosed-with-meningoencephalitis-of-unknown-etiology-2010-2021
#54
JOURNAL ARTICLE
So-Hee Kim, Ye-In Oh, Su-Min Park, Ju Hyun An, Tae-Hee Kim, Sung-Soo Kim, Jae-Gon Ah, Kyoung-Won Seo, Hwa-Young Youn
BACKGROUND: Meningoencephalomyelitis of unknown etiology (MUE) is a comprehensive term for non-infectious inflammatory brain diseases of the central nervous system (CNS) caused by abnormal autoimmune responses. This study aims to compare the differences in survival and clinical response of MUE according to the adjuvant immunosuppressant use. Medical records of 82 dogs diagnosed with MUE were reviewed retrospectively. RESULTS: The overall survival time was 769 days (range 14-2687 days)...
December 12, 2023: BMC Veterinary Research
https://read.qxmd.com/read/38077894/retracted-combination-of-methotrexate-and-leflunomide-is-efficient-and-safe-for-60-patients-with-rheumatoid-arthritis
#55
Computational And Mathematical Methods In Medicine
[This retracts the article DOI: 10.1155/2022/6829358.].
2023: Computational and Mathematical Methods in Medicine
https://read.qxmd.com/read/38073585/antirheumatic-drugs-and-the-risk-of-nonalcoholic-fatty-liver-disease-in-patients-with-rheumatoid-arthritis-a-nationwide-population-based-cohort-study
#56
JOURNAL ARTICLE
Chia-Chu Meng, Der-Yuan Chen, Yi-Hsing Chen, Wen-Nan Huang, Hsin-Hua Chen
OBJECTIVES: To assess the association between antirheumatic drugs and of the risk of nonalcoholic fatty liver disease (NAFLD) in a nationwide rheumatoid arthritis (RA) cohort. METHODS: Using claim data from the 2000-2020 National Health Insurance Research Database, we identified 21 457 incident patients with RA from 2002 to 2020 without prior liver diseases. A time-varying multivariable Cox regression model was applied to estimate for the association of NAFLD with the use of antirheumatic drugs after adjusting potential confounders, show as adjusted hazard ratios (aHRs) with 95% confidence interval (CIs)...
December 11, 2023: International Journal of Rheumatic Diseases
https://read.qxmd.com/read/38053548/anti-cmv-therapy-what-next-a-systematic-review
#57
REVIEW
Claire Gourin, Sophie Alain, Sébastien Hantz
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in immunocompromised patients and after congenital infection. There are currently drugs available to treat HCMV infection, targeting viral polymerase, whose use is complicated by toxicity and the emergence of resistance. Maribavir and letermovir are the latest antivirals to have been developed with other targets. The approval of letermovir represents an important innovation for CMV prevention in hematopoietic stem cell transplant recipients, whereas maribavir allowed improving the management of refractory or resistant infections in transplant recipients...
2023: Frontiers in Microbiology
https://read.qxmd.com/read/38049469/an-injectable-subcutaneous-colon-specific-immune-niche-for-the-treatment-of-ulcerative-colitis
#58
JOURNAL ARTICLE
Kin Man Au, Justin E Wilson, Jenny P-Y Ting, Andrew Z Wang
As a chronic autoinflammatory condition, ulcerative colitis is often managed via systemic immunosuppressants. Here we show, in three mouse models of established ulcerative colitis, that a subcutaneously injected colon-specific immunosuppressive niche consisting of colon epithelial cells, decellularized colon extracellular matrix and nanofibres functionalized with programmed death-ligand 1, CD86, a peptide mimic of transforming growth factor-beta 1, and the immunosuppressive small-molecule leflunomide, induced intestinal immunotolerance and reduced inflammation in the animals' lower gastrointestinal tract...
December 4, 2023: Nature Biomedical Engineering
https://read.qxmd.com/read/38013380/acute-generalized-exanthematous-pustulosis-caused-by-hydroxychloroquine-in-a-patient-with-rheumatoid-arthritis-and-card14-mutation-case-report
#59
JOURNAL ARTICLE
Feng Luo, Xue-Mei Yuan, Hong Xiong, Chang-Ming Chen, Wu-Kai Ma, Xue-Ming Yao
RATIONALE: Acute generalized exanthematous pustulosis (AGEP) is a serious adverse skin reaction characterized by the rapid appearance of densely distributed, small, sterile pustules with erythema. However, its pathogenesis is not fully understood. Hydroxychloroquine is widely used for the treatment of autoimmune diseases. Some patients presenting with AGEP have IL36RN and CARD14 gene mutations. Our report describes a patient with rheumatoid arthritis and AGEP associated with hydroxychloroquine and a newly discovered CARD14 gene mutation...
November 24, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/38003865/network-based-in-silico-analysis-of-new-combinations-of-modern-drug-targets-with-methotrexate-for-response-based-treatment-of-rheumatoid-arthritis
#60
REVIEW
Marjan Assefi, Kai-Uwe Lewandrowski, Morgan Lorio, Rossano Kepler Alvim Fiorelli, Stefan Landgraeber, Alireza Sharafshah
BACKGROUND: Methotrexate (MTX), sulfonamides, hydroxychloroquine, and leflunomide have consistently resulted in remission with relatively mild to moderate adverse effects in patients with rheumatoid arthritis (RA). Modern medications outperform traditional treatments in that they target the pathological processes that underlie the development of RA. METHODS: Following PRISMA guidelines, the authors accomplished a systematic review of the clinical efficacy of RA drugs, including the biologics such as Tumor Necrosis Factor-alpha inhibitors (TNF-α i) like Etanercept, Infliximab, Golimumab, and Adalimumab, kinase inhibitors (JAK inhibitors including Baricitinib and Tofacitanib), SyK inhibitors like Fos-tamatinib, MAPK inhibitors such as Talmapimod, T-cell inhibitors (Abatacept), IL6 blockers (Tocilizumab), and B cells depleters (Rituximab)...
October 29, 2023: Journal of Personalized Medicine
keyword
keyword
8554
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.